LeadArt Technologies
Chemoproteomics and automation dual driver platform Expand the target space and accelerate drug discovery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | $6.0m | Early VC | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
LeadArt Technologies is a venture capital-backed biotechnology company specializing in chemical proteomics and automation technology. The company operates in the pharmaceutical and healthcare sectors, focusing on the discovery of drug targets and the development of new drugs. LeadArt Technologies serves pharmaceutical companies, research institutions, and healthcare providers by offering an automated and intelligent platform for drug target discovery and drug development. The business model revolves around providing access to its proprietary libraries of active compounds and advanced proteomics technology, generating revenue through licensing, partnerships, and direct sales of its products and services. LeadArt Technologies leverages its expertise in chemical proteomics to identify and validate new drug targets, significantly accelerating the drug discovery process. The company’s innovative approach addresses the challenge of understanding the functions of the human body's 20,000+ proteins, of which only a small fraction are well understood. By focusing on proteins with potential therapeutic applications, LeadArt Technologies aims to expand the range of treatable conditions and improve patient outcomes.
Keywords: chemical proteomics, drug discovery, automated platform, biotechnology, pharmaceutical, healthcare, active compounds, protein targets, venture capital, innovation.
